Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $809300.0.

  • Stoke Therapeutics' Gains from Investment Securities rose 1096.94% to $809300.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $809300.0, marking a year-over-year increase of 1096.94%. This contributed to the annual value of $8.0 million for FY2024, which is 2340.51% up from last year.
  • Per Stoke Therapeutics' latest filing, its Gains from Investment Securities stood at $809300.0 for Q3 2025, which was up 1096.94% from $407482.0 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Gains from Investment Securities ranged from a high of $8.3 million in Q4 2022 and a low of $79400.0 during Q3 2022
  • Its 4-year average for Gains from Investment Securities is $1.8 million, with a median of $897712.0 in 2024.
  • In the last 5 years, Stoke Therapeutics' Gains from Investment Securities plummeted by 8911.13% in 2023 and then surged by 78726.49% in 2024.
  • Stoke Therapeutics' Gains from Investment Securities (Quarter) stood at $8.3 million in 2022, then crashed by 89.11% to $901000.0 in 2023, then skyrocketed by 787.26% to $8.0 million in 2024, then plummeted by 89.88% to $809300.0 in 2025.
  • Its last three reported values are $809300.0 in Q3 2025, $407482.0 for Q2 2025, and $2.0 million during Q1 2025.